Biotech https://www.benzinga.com/views/taxonomy/term/19868 en Phio Pharma Shares Are Trading Higher On Cancer Immunotherapies Pact With AgonOx https://www.benzinga.com/general/biotech/21/03/19912406/phio-pharma-shares-are-trading-higher-on-cancer-immunotherapies-pact-with-agonox <p><strong>Phio Pharmaceuticals Corp</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/phio#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">PHIO</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/03/n19909871/phio-pharmaceuticals-and-agonox-inc-announce-collaboration-on-clinical-development-of-novel-t-cell" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">entered into a clinical development collaboration</a>&nbsp;with&nbsp;<strong>AgonOx Inc</strong>&nbsp;to develop novel T cell-based cancer immunotherapies.</p> <ul> <li>The collaboration will use Phio&#39;s lead INTASYL based ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19912406/phio-pharma-shares-are-trading-higher-on-cancer-immunotherapies-pact-with-agonox alt=Phio Pharma Shares Are Trading Higher On Cancer Immunotherapies Pact With AgonOx>Full story available on Benzinga.com</a></p> Biotech Cancer Immunotherapy News Penny Stocks PHIO Health Care Contracts FDA General PHIO News Biotech Penny Stocks Health Care Contracts FDA General Benzinga Mon, 01 Mar 2021 14:01:00 +0000 Vandana Singh 19912406 at https://www.benzinga.com FDA Strikes Out CorMedix's DefenCath Application https://www.benzinga.com/general/biotech/21/03/19912332/fda-strikes-out-cormedixs-defencath-application <p>The&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/03/g19911717/cormedix-receives-complete-response-letter-from-fda-for-defencath-catheter-lock-solution" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">FDA has issued a Complete Response Letter</a>&nbsp;for&nbsp;<strong>CorMedix Inc&#39;s</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/crmd#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">CRMD</a>) marketing application seeking approval for DefenCath (taurolidine/heparin catheter lock solution) for catheter-related bloodstream infections.</p> <ul> <li>FDA noted concerns at the third-party manufacturing facility after reviewing records, ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19912332/fda-strikes-out-cormedixs-defencath-application alt=FDA Strikes Out CorMedix&#039;s DefenCath Application>Full story available on Benzinga.com</a></p> Biotech bloodstream infections CRMD News Health Care Small Cap FDA General CRMD News Biotech Health Care Small Cap FDA General Benzinga Mon, 01 Mar 2021 13:55:46 +0000 Vandana Singh 19912332 at https://www.benzinga.com Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine https://www.benzinga.com/general/biotech/21/03/19911082/satsuma-pharma-shares-rise-after-raising-80m-via-private-placement-plans-new-pivotal-study-for-mi <p><strong>Satsuma Pharmaceuticals Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/stsa#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">STSA</a>)&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/03/g19907895/satsuma-pharmaceuticals-announces-updated-sts101-development-plan" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">will conduct a new Phase 3 efficacy trial</a>&nbsp;for STS101 (dihydroergotamine (DHE) nasal powder) as an acute treatment option for migraine.</p> <ul> <li>The study will start in mid-2021, with topline data expected in the second half of 2022.</li> <li>The new Phase 3 trial takes into account findings from the previous Phase 3 EMERGE study.</li> <li>STS101&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/20/09/17452788/satsumas-migraine-drug-flunks-late-stage-study-stock-sinks-to-record-low" style="color: rgb(14, 16, 26); background: ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19911082/satsuma-pharma-shares-rise-after-raising-80m-via-private-placement-plans-new-pivotal-study-for-mi alt=Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine>Full story available on Benzinga.com</a></p> Biotech Migraines News Phase 3 Trial STSA Health Care Offerings FDA General STSA US8593193035 News Biotech Health Care Offerings FDA General Benzinga Mon, 01 Mar 2021 13:43:58 +0000 Vandana Singh 19911082 at https://www.benzinga.com Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer https://www.benzinga.com/general/biotech/21/03/19907806/kazia-therapeutics-licenses-cantrixil-to-oasmia-pharmaceutical-for-ovarian-cancer <p><strong>Kazia Therapeutics Ltd</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/kzia#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">KZIA</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.prnewswire.co.uk/news-releases/kazia-licenses-cantrixil-a-clinical-stage-first-in-class-ovarian-cancer-drug-candidate-to-oasmia-pharmacetical-ab-885769945.html" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">entered an exclusive worldwide licensing</a>&nbsp;agreement with&nbsp;<strong>Oasmia Pharmaceutical AB</strong>&nbsp;(OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cancer.</p> <ul> <li>The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer.</li> <li>Oasmia&#39;s lead ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19907806/kazia-therapeutics-licenses-cantrixil-to-oasmia-pharmaceutical-for-ovarian-cancer alt=Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer>Full story available on Benzinga.com</a></p> Biotech KZIA News OASMY Ovarian Cancer Health Care Contracts FDA General KZIA OASMY News Biotech Health Care Contracts FDA General Benzinga Mon, 01 Mar 2021 13:39:17 +0000 Vandana Singh 19907806 at https://www.benzinga.com Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis https://www.benzinga.com/general/biotech/21/03/19907289/aslan-pharmaceuticals-shares-are-trading-higher-on-positive-aslan004-data-in-atopic-dermatitis <p><strong>Aslan Pharmaceuticals Ltd</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/asln#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">ASLN</a>) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe atopic dermatitis (AD).</p> <ul> <li>Subcutaneous delivery of ASLAN004 was shown to be well tolerated across all doses (200mg, 400mg, and 600mg) and showed improvements compared to placebo in all ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19907289/aslan-pharmaceuticals-shares-are-trading-higher-on-positive-aslan004-data-in-atopic-dermatitis alt=Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis>Full story available on Benzinga.com</a></p> ASLN atopic dermatitis Biotech News Penny Stocks Contracts FDA General ASLN News Biotech Penny Stocks Contracts FDA General Benzinga Mon, 01 Mar 2021 13:18:12 +0000 Vandana Singh 19907289 at https://www.benzinga.com Merck's Cough Drug Gefapixant Application Accepted For US Review https://www.benzinga.com/general/biotech/21/03/19908728/mercks-cough-drug-gefapixant-application-accepted-for-us-review <p>The FDA has accepted&nbsp;<strong>Merck &amp; Co Inc&#39;s</strong>&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/mrk#NYSE" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">MRK</a>) marketing application seeking approval for gefapixant,&nbsp;<a class="editor-rtfLink" href="http://www.benzinga.com/pressreleases/21/03/b19907676/u-s-fda-accepts-mercks-gefapixant-new-drug-application-for-review" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">for review</a>.</p> <ul> <li>The selective P2X3 receptor antagonist is being developed to treat refractory chronic cough ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19908728/mercks-cough-drug-gefapixant-application-accepted-for-us-review alt=Merck&#039;s Cough Drug Gefapixant Application Accepted For US Review>Full story available on Benzinga.com</a></p> Biotech chronic cough MRK News Health Care FDA General MRK US58933Y1055 News Biotech Health Care FDA General Benzinga Mon, 01 Mar 2021 13:12:54 +0000 Vandana Singh 19908728 at https://www.benzinga.com Perrigo Divests Generic Pharma Business For $1.55B To Altaris Capital https://www.benzinga.com/general/biotech/21/03/19909048/perrigo-divests-generic-pharma-business-for-1-55b-to-altaris-capital <p><strong>Perrigo Company Plc&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prgo#NYSE">PRGO</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/03/n19908207/perrigo-announces-agreement-to-sell-generic-rx-business-for-1-55-billion-in-total-consideration" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">agreed to sell its Generic Rx Pharmaceuticals business</a>&nbsp;to Altaris Capital Partners for $1.55 billion.&nbsp;</p> <ul> <li>The price included a $1.5 billion payment in cash. Altaris will also assume more than $50 million in potential R&amp;D milestone payments and contingent purchase obligations with third-party partners.</li> <li>Perrigo CEO and President ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19909048/perrigo-divests-generic-pharma-business-for-1-55b-to-altaris-capital alt=Perrigo Divests Generic Pharma Business For $1.55B To Altaris Capital>Full story available on Benzinga.com</a></p> Biotech M&A News PRGO Health Care Asset Sales General PRGO US7142901039 News M&A Biotech Health Care Asset Sales General Benzinga Mon, 01 Mar 2021 13:08:39 +0000 Vandana Singh 19909048 at https://www.benzinga.com Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March https://www.benzinga.com/pressreleases/21/03/g19909786/onconova-therapeutics-to-participate-in-three-investment-conferences-during-the-month-of-march <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONTX#NASDAQ" rel="nofollow">ONTX</a>) ("Onconova"), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows:<br /></p> <ul type="disc"> <li style="text-align:justify;">The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March 9-10, 2021</li> <li style="text-align:justify;">The Virtual 33rdĀ Annual Roth Conference with one-on-one meetings being held March 15-17, 2021</li> <li style="text-align:justify;">The Maxim Group Emerging Growth Virtual Conference being held March 17-18, 2021 with one-on-one meetings scheduled after the event<br /></li> </ul> <p align="justify">The Roth Capital Partners presentation will be prerecorded and available in the Investors &amp; Media section of the Company&#039;s website beginning today. Institutional and other investors interested in scheduling a one-on-one meeting with Onconova during any of these conferences should contact their sales representative at the sponsoring investment bank.</p> <p align="justify"><strong>About Onconova Therapeutics, Inc. </strong><br />Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The ...</p><p><a href=https://www.benzinga.com/pressreleases/21/03/g19909786/onconova-therapeutics-to-participate-in-three-investment-conferences-during-the-month-of-march alt=Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March>Full story available on Benzinga.com</a></p> Biotech News ONTX Health Care Retail Sales Press Releases General Mon, 01 Mar 2021 13:00:00 +0000 Globe Newswire 19909786 at https://www.benzinga.com Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China https://www.benzinga.com/pressreleases/21/03/g19909712/starton-therapeutics-and-haisco-pharmaceutical-announce-an-exclusive-licensing-agreement-to-develo <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">PARAMUS, N.J. and CHENGDU, China, March 01, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (Starton), a US-based privately held clinical-stage biopharmaceutical company, and Haisco Pharmaceutical Group Co., Ltd. (Haisco), a leading China-based pharmaceutical company, announced today that they have entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ, a once-weekly transdermal olanzapine delivery system in development for Nausea and Vomiting, in Mainland China.<br /></p> <p align="justify">Starton and Haisco are preparing to launch clinical studies in chemotherapy induced nausea and vomiting (CINV), followed by additional nausea and vomiting indications. Starton has completed a human bioavailability study with STAR-OLZ, which successfully delivered therapeutic blood levels and displayed acceptable tolerability.</p> <p align="justify">Pedro Lichtinger, CEO of Starton Therapeutics, commented, "Haisco is an ideal partner for our STAR-OLZ product. In addition to being a respected pharmaceutical company in China, Haisco leads in antiemetic sales in China and has several antiemetics products in the market and in development. Their knowledge and commercial presence in the most price sensitive market will maximize the potential value that STAR-OLZ brings to patients."</p> <p align="justify">Junmin Wang, Chairman of Haisco Board, commented, "Haisco has built a strong profile in tumor antiemetic area. Our Dolasteron injectable shares a great portion in the antiemetic market in China. In-licensing STAR-OLZ to China brings a more effective and convenient treatment option to Chinese cancer patients and adds on a novel means to differentiate our present antiemetic offerings. We look forward to closely collaborating with Starton to efficiently develop this product to ...</p><p><a href=https://www.benzinga.com/pressreleases/21/03/g19909712/starton-therapeutics-and-haisco-pharmaceutical-announce-an-exclusive-licensing-agreement-to-develo alt=Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China>Full story available on Benzinga.com</a></p> Biotech Licensing Press Releases General Mon, 01 Mar 2021 13:00:00 +0000 Globe Newswire 19909712 at https://www.benzinga.com Athenex Shares Are Trading Lower After FDA Rejected Oral Paclitaxel Plus Encequidar Application In Breast Cancer https://www.benzinga.com/general/biotech/21/03/19908597/athenex-shares-are-trading-lower-after-fda-rejected-oral-paclitaxel-plus-encequidar-application-i <p>The&nbsp;<a class="editor-rtfLink" href="https://www.globenewswire.com/fr/news-release/2021/03/01/2184118/0/en/Athenex-Receives-FDA-Complete-Response-Letter-for-Oral-Paclitaxel-Plus-Encequidar-for-the-Treatment-of-Metastatic-Breast-Cancer.html" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">FDA has issued a complete response letter</a>&nbsp;(CRL) for&nbsp;<strong>Athenex Inc&rsquo;s</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/atnx#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">ATNX</a>) marketing application seeking approval for oral paclitaxel plus encequidar to treat metastatic breast cancer.</p> <ul> <li>The CRL ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19908597/athenex-shares-are-trading-lower-after-fda-rejected-oral-paclitaxel-plus-encequidar-application-i alt=Athenex Shares Are Trading Lower After FDA Rejected Oral Paclitaxel Plus Encequidar Application In Breast Cancer>Full story available on Benzinga.com</a></p> ATNX Biotech breast cancer News Health Care Small Cap FDA General ATNX News Biotech Health Care Small Cap FDA General Benzinga Mon, 01 Mar 2021 12:28:21 +0000 Vandana Singh 19908597 at https://www.benzinga.com AstraZeneca, Junshi Bio In Commercialization Pact For Toripalimab In China https://www.benzinga.com/general/biotech/21/03/19906353/astrazeneca-junshi-bio-in-commercialization-pact-for-toripalimab-in-china <p><strong>AstraZeneca Plc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/azn#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">AZN</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.globenewswire.com/news-release/2021/03/01/2183839/0/en/Junshi-Biosciences-and-AstraZeneca-Announce-Strategic-Collaboration-to-Commercialize-Toripalimab-in-China.html" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">announced a deal</a>&nbsp;with&nbsp;<strong>Shanghai Junshi Biosciences Co Ltd</strong>&nbsp;to ...</p><p><a href=https://www.benzinga.com/general/biotech/21/03/19906353/astrazeneca-junshi-bio-in-commercialization-pact-for-toripalimab-in-china alt=AstraZeneca, Junshi Bio In Commercialization Pact For Toripalimab In China>Full story available on Benzinga.com</a></p> AZN Biotech News Urothelial Cancer Health Care FDA General AZN US0463531089 News Biotech Health Care FDA General Benzinga Mon, 01 Mar 2021 11:17:52 +0000 Vandana Singh 19906353 at https://www.benzinga.com Regeneron's Single-Dose REGN1908-1909 Shows Rapid, Durable Benefit In Cat-Allergic Asthma Patients https://www.benzinga.com/general/biotech/21/03/19906300/regenerons-single-dose-regn1908-1909-shows-rapid-durable-benefit-in-cat-allergic-asthma-patients <p><strong>Regeneron Pharmaceuticals Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/regn#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">REGN</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/02/n19900679/regeneron-announces-positive-phase-2-data-evaluating-fel-d-1-antibody-cocktail-in-cat-allergic-pat" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">announced detailed results</a>&nbsp;from a Phase 2 proof-of-concept trial evaluating an antibody cocktail, REGN1908-1909, in cat-allergic patients with mild asthma.</p> <ul> <li>Regeneron presented the results at the virtual 2021 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting.</li> <li>The trial results showed that a single dose ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19906300/regenerons-single-dose-regn1908-1909-shows-rapid-durable-benefit-in-cat-allergic-asthma-patients alt=Regeneron&#039;s Single-Dose REGN1908-1909 Shows Rapid, Durable Benefit In Cat-Allergic Asthma Patients>Full story available on Benzinga.com</a></p> asthma Biotech News REGN FDA General REGN US75886F1075 News Biotech FDA General Benzinga Mon, 01 Mar 2021 11:14:25 +0000 Vandana Singh 19906300 at https://www.benzinga.com ElectroCore's Shares Are Trading Higher After Australia Ok'd Vagus Nerve Stimulator For Headaches https://www.benzinga.com/general/biotech/21/03/19906477/electrocores-shares-are-trading-higher-after-australia-okd-vagus-nerve-stimulator-for-headaches <p>The Australian Therapeutic Goods Administration&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/02/g19903345/electrocore-inc-announces-exclusive-distribution-agreement-with-medistar-following-regulatory-appr" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">has approved</a>&nbsp;<strong>ElectroCore Inc&#39;s</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/ecor#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">ECOR</a>) gammaCore Sapphire family of products, including a non-invasive vagus nerve stimulator (nVNS) for primary headache ...</p><p><a href=https://www.benzinga.com/general/biotech/21/03/19906477/electrocores-shares-are-trading-higher-after-australia-okd-vagus-nerve-stimulator-for-headaches alt=ElectroCore&#039;s Shares Are Trading Higher After Australia Ok&#039;d Vagus Nerve Stimulator For Headaches>Full story available on Benzinga.com</a></p> Australian Therapeutic Goods Administration Biotech ECOR headache News Penny Stocks Contracts FDA General ECOR News Biotech Penny Stocks Contracts FDA General Benzinga Mon, 01 Mar 2021 11:10:09 +0000 Vandana Singh 19906477 at https://www.benzinga.com Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies https://www.benzinga.com/general/biotech/21/03/19906037/evotec-chinook-therapeutics-ink-development-pact-for-chronic-kidney-diseases-therapies <p><strong>Chinook Therapeutics Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/kdny#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">KDNY</a>) and <strong>Evotec SE</strong>&nbsp;(OTCMKTS: EVTCY) have&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/03/ac19905085/evotec-and-chinook-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-novel-" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">collaborated for the discovery and development</a>&nbsp;of precision medicine therapies for patients with chronic kidney diseases (CKD).</p> <ul> <li>Based on Evotec&#39;s proprietary comprehensive molecular datasets, ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/03/19906037/evotec-chinook-therapeutics-ink-development-pact-for-chronic-kidney-diseases-therapies alt=Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies>Full story available on Benzinga.com</a></p> Biotech Chronic Kidney Disease EVOTF EVTCY KDNY M&A News Health Care Contracts Small Cap General EVTCY EVOTF KDNY News M&A Biotech Health Care Contracts Small Cap General Benzinga Mon, 01 Mar 2021 10:22:28 +0000 Vandana Singh 19906037 at https://www.benzinga.com BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder https://www.benzinga.com/general/biotech/21/03/19905886/bridgebio-pharma-gets-first-fda-approval-for-rare-genetic-metabolic-disorder <p><strong>BridgeBio Pharma Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/bbio#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">BBIO</a>) and affiliate&nbsp;<strong>Origin Biosciences Inc</strong>&nbsp;have received the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/02/g19902183/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda-approval-of-nulibry-fosdenopterin-t" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">FDA approval for Nulibry</a>&nbsp;(fosdenopterin) Injection to reduce the risk of ...</p><p><a href=https://www.benzinga.com/general/biotech/21/03/19905886/bridgebio-pharma-gets-first-fda-approval-for-rare-genetic-metabolic-disorder alt=BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder>Full story available on Benzinga.com</a></p> BBIO Biotech molybdenum cofactor deficiency News Orphan Drug Designation Health Care FDA General BBIO News Biotech Health Care FDA General Benzinga Mon, 01 Mar 2021 10:17:21 +0000 Vandana Singh 19905886 at https://www.benzinga.com